Many promising treatments for COVID-19 are in development and, if one or more of these treatments prove safe and effective, it will be imperative to be able to manufacture these therapies at scale, to meet extensive world-wide demand. However, scaling up production of these treatments will be challenging. Moreover, existing manufacturing capacity for a number of the most promising treatments (e.g., monoclonal antibodies and other biologics) is already limited. The United States already faces ongoing shortages of many critical drug products, and the need for additional production will strain our existing capacity even further.
This webinar explores issues, strategies, and policies to avoid or mitigate manufacturing bottlenecks for COVID-19 therapeutics by developing new manufacturing capacity and repurposing existing manufacturing capacity.